{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:44:48Z","timestamp":1791902688535,"version":"4.3.4"},"reference-count":40,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2004,2,5]],"date-time":"2004-02-05T00:00:00Z","timestamp":1075939200000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Merck & Company, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2004,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the efficacy and safety of etoricoxib and indomethacin in the treatment of patients with acute gout.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A randomized, double\u2010blind, active\u2010comparator study was conducted at 42 sites. A total of 189 men and women (\u226518 years of age) who were experiencing an acute attack (\u226448 hours) of clinically diagnosed gout were treated for 8 days with etoricoxib, 120 mg\/day (n = 103), or indomethacin, 50 mg 3 times a day (n = 86). The primary efficacy end point was the patient's assessment of pain in the study joint (0\u20134\u2010point Likert scale) over days 2\u20135. Safety was assessed by adverse experiences (AEs) occurring during the trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Etoricoxib demonstrated clinical efficacy comparable to that of indomethacin in terms of the patient's assessment of pain in the study joint. The difference in the mean change from baseline over days 2\u20135 was \u20130.08 (95% confidence interval \u20130.29, 0.13) (<jats:italic>P<\/jats:italic> = 0.46), which fell within the prespecified comparability bounds of \u20130.5 to 0.5. Secondary end points over the 8\u2010day study, including the onset of efficacy, reduction in signs of inflammation, and patient's and investigator's global assessments of response to therapy, confirmed the comparable efficacy of the two treatments. The etoricoxib\u2010treated patients had a numerically lower incidence of AEs (43.7%) than did the indomethacin\u2010treated patients (57.0%) and a significantly lower incidence of drug\u2010related AEs (16.5% versus 37.2%; <jats:italic>P<\/jats:italic> &lt; 0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Etoricoxib at a dosage of 120 mg once daily was confirmed to be an effective treatment for acute gout. Etoricoxib was comparable in efficacy to indomethacin at a dosage of 50 mg 3 times daily, and it was generally safe and well tolerated.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.20007","type":"journal-article","created":{"date-parts":[[2004,2,9]],"date-time":"2004-02-09T18:29:18Z","timestamp":1076351358000},"page":"598-606","source":"Crossref","is-referenced-by-count":122,"title":["Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: A randomized controlled trial"],"prefix":"10.1002","volume":"50","author":[{"given":"Bernard R.","family":"Rubin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Navarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Antigua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Londo\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith G.","family":"Pryhuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erluo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl K.","family":"Najarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Petruschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zafer E.","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory P.","family":"Geba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,2,5]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"925","article-title":"Gout and hyperuricemia","volume":"59","author":"Harris MD","year":"1999","journal-title":"Am Fam Physician"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)89546-0"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199813030-00006"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-001-0049-7"},{"key":"e_1_2_7_6_2","first-page":"401","article-title":"Crystal\u2010induced arthritis","volume":"63","author":"Reginato A","year":"1982","journal-title":"Arch Phys Med Rehabil"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4831-6750-3.50006-8"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(21)00969-8"},{"key":"e_1_2_7_9_2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.5694\/j.1326-5377.2000.tb124075.x","article-title":"Clinical manifestations of gout and their management","volume":"172","author":"Van Doornum S","year":"2000","journal-title":"Med J Aust"},{"key":"e_1_2_7_10_2","first-page":"1232","article-title":"Radiologic features of gout","volume":"54","author":"Buckley TJ","year":"1996","journal-title":"Am Fam Physician"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.5.1769"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(98)00323-4"},{"key":"e_1_2_7_13_2","first-page":"1799","article-title":"Diagnosis and management of gout","volume":"59","author":"Pittman JR","year":"1999","journal-title":"Am Fam Physician"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602153340707"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1991.tb02629.x"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00362-9"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00112-6"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199906173402407"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8553(05)70109-6"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00366-6"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199753040-00003"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.154330000.x"},{"issue":"1","key":"e_1_2_7_23_2","first-page":"SI31","article-title":"Gastrointestinal safety and tolerability of nonselective nonsteroidal anti\u2010inflammatory agents and cyclooxygenase\u20102\u2010selective inhibitors","volume":"69","author":"Peura DA","year":"2002","journal-title":"Cleve Clin J Med"},{"issue":"1","key":"e_1_2_7_24_2","first-page":"SI40","article-title":"Outcomes studies of the gastrointestinal safety of cyclooxygenase\u20102 inhibitors","volume":"69","author":"Scheiman JM","year":"2002","journal-title":"Cleve Clin J Med"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011233432103"},{"key":"e_1_2_7_26_2","first-page":"558","article-title":"Etoricoxib (MK\u20100663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase\u20102","volume":"296","author":"Riendeau D","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.69.Suppl_1.SI20"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079902125000282"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7352.1488"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780200320"},{"key":"e_1_2_7_31_2","first-page":"230","volume-title":"Primer on the rheumatic diseases","author":"Terkeltaub RA","year":"1997"},{"key":"e_1_2_7_32_2","first-page":"1422","article-title":"Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double\u2010blind comparative study","volume":"15","author":"Altman RD","year":"1988","journal-title":"J Rheumatol"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1987.tb03132.x"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-72-3-430"},{"key":"e_1_2_7_35_2","first-page":"63","article-title":"Treatment of acute gouty arthritis with piroxicam","volume":"3","author":"Karachalios GN","year":"1985","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1975.tb01465.x"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(95)70037-4"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007999109111513"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/17.4.205"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262180-00006"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363010-00003"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.20007","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.20007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T14:52:10Z","timestamp":1696949530000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.20007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["10.1002\/art.20007"],"URL":"https:\/\/doi.org\/10.1002\/art.20007","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,2]]}}}